| 前收市價 | 34.25 |
| 開市 | 34.25 |
| 買盤 | 30.40 |
| 賣出價 | 34.30 |
| 拍板 | 165.00 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 34.25 - 34.25 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 8 |
InvestorPlaceJune’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Wall Street regards the healthcare sector as a constant source of innovation, while biotechnology stands at the pinnacle of groundbreaking medical advancements. The long-term potential of robust biotech stocks to buy remains undeniable for investors. As the summer season kicks in, several biotech companies exhibit characteristics that could ignite this potential summertime surge. Promising clinical trial results, significant product launches, or strategic partnerships could drive this momentum.
Insider MonkeyAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript May 2, 2024 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.52272, expectations were $-0.75. ALNY isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for […]
ZacksAlnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
